Navigation Links
Savient Pharmaceuticals to Hold Third Quarter 2010 Financial Results Conference Call on Friday, November 5, 2010
Date:10/27/2010

EAST BRUNSWICK, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that the company will release financial results for the third quarter 2010 following the close of the market on Thursday, November 4, 2010.

Paul Hamelin, President, and David Gionco, Group Vice President, Chief Financial Officer & Treasurer, will host an investment community conference call beginning at 9:00 a.m. Eastern Time on Friday, November 5, 2010 to discuss these results and to answer questions.

To participate by telephone, please dial 888-357-3694 (Domestic) or 973-890-8276 (International). The conference identification number is 21650025. The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com. Please log on to Savient's website fifteen minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.

A telephone replay will be available from 12:00 p.m. Eastern Time on November 5, 2010 through 11:59 p.m. Eastern Time on November 12, 2010 by dialing 800-642-1687 (Domestic) or 706-645-9291 (International) and entering conference ID number 21650025.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA(TM) (pegloticase), which was approved by the FDA on September 14, 2010 for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Du
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. Savient Provides Update on Pegloticase BLA
3. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
7. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
8. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
9. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
10. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
11. Savient Pharmaceuticals To Hold First Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... LOS ANGELES , Dec. 17, 2014 /PRNewswire/ ... that the US Patent and Trademark Office (USPTO) ... candidate ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting ... glioblastoma. The claims of US Patent No. 8,871,211, ... treating neural cancer by administering a dendritic cell ...
(Date:12/17/2014)... MARLBOROUGH, Mass. , Dec. 17, 2014 /PRNewswire/ ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced completion of enrollment in ... results from the 3-month observations confirmed the 1-month ... year:  Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:12/17/2014)... -- PCCA received the Autism Hope Alliance,s (AHA) ... seal for best practices in meeting needs in ... materials and goods that meet strict criteria and ... by autism often have unique physical or psychological ... in food and medicine – for instance casein, ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3
... 2011 IOD Incorporated, a leading provider of integrated ... today announced it has received the federal ... Meaningful Use certification of its PRISM platform for both ... deems the software capable of enabling providers to qualify ...
... Arecor Limited has entered into ... to assess Arecor,s advanced protein formulation technologies for ... drugs.  Under this agreement, Arecor will develop stable ... and peptide drug candidates developed by Lilly.  In addition, ...
Cached Medicine Technology:IOD Incorporated's PRISM™ Receives ONC-ATCB Certification by Drummond Group 2IOD Incorporated's PRISM™ Receives ONC-ATCB Certification by Drummond Group 3Arecor Forms Collaboration With Lilly to Develop Advanced Formulations of Protein Therapeutics 2
(Date:12/17/2014)... (PRWEB) December 17, 2014 Unidesk ... Osteopathic Medicine (ACOM), which welcomed its inaugural class ... Infrastructure (VDI) to seamlessly support bring your own ... and teaching – experience. The solution, comprised of ... , Dell server and storage infrastructure ...
(Date:12/17/2014)... December 17, 2014 No matter how ... able to eradicate the head louse parasite—a common childhood ... parents. Each year between six and twelve million individuals ... Miami-based lice removal treatment company comes to the rescue, ... environmentally friendly. With its track record of customer service, ...
(Date:12/17/2014)... Dec. 16, 2014 (HealthDay News) -- Expectant parents should ... and Drug Administration recommends. Use of ultrasound imaging ... is not entirely risk-free, the agency warns. ... harm due to ultrasound imaging and heartbeat monitors, prudent ... is important," Shahram Vaezy, an FDA biomedical engineer, said ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. ... in America, and work commitment is a big reason why, ... killer," said Dr. Mathias Basner, an assistant professor of sleep ... School of Medicine. A time-use survey of nearly 125,000 ... the main activity exchanged for sleep. Short sleepers -- those ...
(Date:12/15/2014)... Palm Beach, FL (PRWEB) December 15, 2014 ... Care , knows that holidays can be a daze of ... From slips and falls while decking halls, to burns when ... plenty of holiday hazards that can happen at any time. ... for pain, MD Now has made a list of helpful ...
Breaking Medicine News(10 mins):Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3
... of fetuin-A were linked to later disease development, study ... Rising levels of a blood protein called fetuin-A may ... new research suggests. , Reporting in the current issue ... , researchers from the University of California, San Diego, ...
... HumanWare expands its low vision,product line with the announcement ... conference on low vision being held in Montreal this,week. ... serve the needs,of the growing number of people with ... even with the most powerful prescription glasses., HumanWare,s ...
... keeps muscles from getting too big may optimize recovery of ... inhibitors in mice with limb injuries, first to see which ... says Dr. Mark Hamrick, bone biologist in the Medical College ... "Fifty to 60 percent of the injuries occurring in Iraq ...
... Young to expand sales efforts for nationwide managed care ... a wholly,owned subsidiary of GAB Robins North America, Inc., ... Young has joined its sales,team as vice president of ... great asset to MedInsights as we expand our national,sales ...
... Need for Parents to Include Life Insurance ... in Their College-Funding Plans, ARLINGTON, ... -- turns. When a loved one dies, it can be particularly,painful. ... that comes when the head of the household dies,prematurely with little ...
... is a,statement by Matthew L. Myers, President, Campaign for ... taken important action to,protect public health by proposing to ... ratings are based on an,FTC-approved testing method or that ... warns tobacco companies that they risk legal action by,the ...
Cached Medicine News:Health News:A Blood Marker Could Spot Diabetes Risk 2Health News:A Blood Marker Could Spot Diabetes Risk 3Health News:HumanWare introduces four new portable video magnifiers for low vision 2Health News:Myostatin inhibitors may improve recovery of wartime limb injuries 2Health News:Myostatin inhibitors may improve recovery of wartime limb injuries 3Health News:MedInsights, Inc. Selects Douglas Young as VP - Sales & Product Development 2Health News:LIFE Foundation Asks Public to Vote to Determine its $5,000 Life Lessons College Scholarship Winner 2Health News:LIFE Foundation Asks Public to Vote to Determine its $5,000 Life Lessons College Scholarship Winner 3Health News:FTC Acts to Prevent Tobacco Industry Deception About Tar, Nicotine Levels; Congress Should Go Further by Giving FDA Authority Over Tobacco Products 2Health News:FTC Acts to Prevent Tobacco Industry Deception About Tar, Nicotine Levels; Congress Should Go Further by Giving FDA Authority Over Tobacco Products 3
... The RapidAMP test is an immunochromatography ... It is,designed for qualitative determination of ... cut-off level of 1000 ng/mL. This ... the point of care,location and is ...
The RapidBARBITURATE test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of barbiturates and in human urine specimens above a cut-off level of 3...
... ACL TOP is a fully ... volume labs maximize labor resources and ... provides clotting, chromogenic and immunoturbidimetric testing ... routine and specialty assays. It's also ...
... Quality Analysis System) developed by Pablo Artal, ... first diagnostic tool for ophthalmology that provides ... system. Never before has an ophthalmologist had ... quality of vision. , ,OQAS works by ...
Medicine Products: